Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

- Age ≥ 18yrs; BMI 18-35 kg/m2

- β-thalassaemia intermedia or compound heterozygous HbE/β-thalassaemia

- Non-transfusion dependent: ≤ 5 units red cells in last 6 months and transfusion-free for ≥8 weeks

- Hb between 5 & 11 g/dL

- Ferritin > 250 µg/L and /or liver iron ≥ 3mg Fe/g dry weight and TSAT >40%

- Haemoglobin S/β-thalassaemia, homozygous β-0 thalassaemia or α thalassaemia

- ALT/AST > 1.5 x upper limit normal or cirrhosis

- eGFR < 60 mL/min/1.73m2

- Platelets <100 or > 1000 x 109/L

- Untreated B12/folate deficiency

- Iron chelation therapy unless stable for ≥8 weeks

- Daily NSAID, therapeutic dose anticoagulant, ESA ≤12 weeks or stable dosing of hydroxyurea ≤ 6 months

- Significant cardiac disease (MI in 6 months, NYHA class III-IV heart failure, long QT)

- HIV or active hepatitis B/C or malignancy within 5 year